Item 8.01 Other Events.
On August 17, 2021, Gritstone bio, Inc. (the "Company" or "Gritstone") announced
that it entered into a funding agreement with the Coalition for Epidemic
Preparedness Innovations (CEPI) for up to $20.6 million to advance the
development of Gritstone's CORAL COVID-19 vaccine program with an initial focus
in South Africa. Under the terms of the agreement, CEPI will fund a multi-arm
Phase I study evaluating the CORAL program's SAM vaccine in naïve, convalescent,
and HIV positive patients. The funding will also support pre-clinical studies,
scale-up and formulation development to enable more stable drug product.
A copy of the press release with the foregoing announcement is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Exhibit
No. Description
99.1 Press Release dated August 17, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses